ArticleScientific reports2026
Selective antagonism of adenosine A2A receptor reduces hypobaric hypoxia-induced neuroinflammation by inhibiting cGAS-STING pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From danger to resolution: targeting purinergic signaling in CNS diseases.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Nucleotide Metabolism in Health and Disease.MedComm · 2026Review
- Adenosine Signaling as a Central Integrative Network in Cellular Stress Responses and a Therapeutically Actionable Target in Human Disease.Biomolecules · 2026Review
- Purinergic modulation in Parkinson's disease: the dual role of istradefylline in motor and cognitive outcomes.Purinergic signalling · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
High altitude with insufficient oxygen supply poses a great threat to public health. Short- or long-term hypobaric hypoxia (HY) exposure significantly impairs cognitive function. Adenosine receptors with four subtypes participate in the pathogenesis of multiple neurodegenerative diseases. However, the functions of adenosine receptors in HY-induced cognitive impairment are poorly explored. A mouse model of HY-induced cognitive impairment was established using a hypobaric chamber to simulated hypoxia conditions equal to an altitude of 7000 m for 14 days. The levels of adenosine receptors (ADORA1, ADORA2A, ADORA2B and ADORA3) in the hippocampus of cognitively impaired mice was detected by Quantitative Real-time Polymerase Chain Reaction (qPCR) and Western blot. The ADORA2A antagonist KW6002 was administered from day 4 to day 14 of HY exposure. Neurobehavioral function assessments, histopathological staining, evans blue extravasation and transmission electron microscopy were used to evaluate the therapeutic effects of KW6002 in vivo. RNA-seq, qPCR, ELISA, immunofluorescence, and western blots were performed to investigate the underlying mechanism of adenosine A2A receptor in HY-induced cognitive impairment. Adenosine A2A receptor was uniquely upregulated after HY exposure, while the other three subtypes (ADORA1, ADORA2B and ADORA3) were barely influenced. Selective antagonism of ADORA2A by KW6002 strongly attenuated mice neurological deficits and histopathological injuries. Furthermore, KW6002 enhanced the integrity of blood-brain barrier (BBB), mitigated oxidative stress and neuroinflammation. KW6002 potently inhibited the production of endogenous cAMP and cascading mitochondrial protein levels of EPAC1 and VDAC1, which alleviated the release of the mtDNA to cytoplasm via mitochondrial permeability transition pore (MPTP). Less cytosolic mtDNA accumulation after KW6002 treatment attenuated HY-induced activation of cGAS-STING inflammatory signaling pathway. ADORA2A activation mediates HY cognitive impairment, which is achieved by activating EPAC1 and VDAC1 to mediate mtDNA release and cGAS-STING signaling pathway to drive neuroinflammation cascade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.